Sigilon Therapeutics, Inc. (SGTX)

They are a clinical-stage biotechnology company pioneering a new class of therapeutics and seeking to develop functional cures for patients with chronic diseases by providing stable and durable levels of therapeutic molecules to patients. They have developed their Shielded Living Therapeutics, or SLTx, platform, which combines advanced cell engineering with cutting-edge innovations in biocompatible materials and enables their product candidates to produce a wide range of therapeutic molecules that may be missing or deficient, such as proteins, antibodies and hormones. They are designing their product candidates to be off-the-shelf, durable, controllable and redosable, without requiring modification of the patient's genes or immunosuppression. Their lead product candidate, SIG-001, is designed to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A by continuously secreting human FVIII. They received acceptance of their IND submission in the United States in August 2020 and their CTA in the United Kingdom in May 2020. They have initiated their Phase 1/2 clinical study of SIG-001 in Hemophilia A, with the first patient dosed in October 2020.

Industry
Pharmaceuticals

CEO	CFO
Rogerio Vivaldi Coelho	Glenn Reicin

Rogerio Vivaldi Coelho, M.D., has served as our President and Chief Executive Officer and as a member of our board of directors since 2018. Prior to joining Sigilon, Dr. Vivaldi served as Executive Vice President and Chief Global Therapeutics Officer at Bioverativ Inc. from 2016 until it was acquired by Sanofi in 2018, and served as Chief Commercial Officer at Spark Therapeutics between 2014 and 2016. Before that he led Genzyme's rare disease business as President of both the rare disease business and the renal & endocrine group, as well as Senior Vice President and General Manager of Genzyme's Latin America Group during his 20-year tenure at Genzyme. Dr. Vivaldi holds his medical degree from the Universidade do Rio de Janeiro. He completed a residency in endocrinology at the Universidade do Estado do Rio de Janeiro and a fellowship at Mount Sinai Hospital Center in New York in the department of genetics, focusing on Gaucher disease. Dr. Vivaldi holds an M.B.A. degree from COPPEAD, Universidade Federal do Rio de Janeiro. We believe that Dr. Vivaldi is qualified to serve on our board of directors based on his extensive experience in the pharmaceutical industry and his expansive knowledge of our company due to his role as our President and Chief Executive Officer.

Glenn Reicin has served as our Chief Financial Officer since 2019. Mr. Reicin is a biotechnology and medical technology executive with experience across finance, operations and investor relations. From 2013 until 2019, Mr. Reicin served as President of Greyrock Biomedical Advisors, Ltd., which provides a range of deal sourcing, valuation, due diligence and management consulting services for companies in the healthcare space. Mr. Reicin currently serves on the board of directors of Amplitude Healthcare Acquisition Corporation, a public specialty purpose acquisition company. Previously, he served as an Executive-in-Resident at Covidien Plc and Managing Director at Skyline Ventures Management LLC. At Skyline Ventures Management LLC, he served as an active board member at a number of biotech firms, including Novasys Medical Inc., a maker of minimally invasive treatments for female incontinence, SI-Bone Inc., a developer of a minimally invasive surgical treatment for sacroiliac joint disorders, and Spinal Motion, Inc., a developer of artificial disc implants to preserve motion at the treated spinal segment of the body. Mr. Reicin held various position of increasing responsibility at Morgan Stanley where he served as a Managing Director at Morgan Stanley where he headed their Healthcare Equity Research team. He started his career at Morgan Stanley where he became a Managing Director in equity research covering medical technology. His sell-side career spanned 18 years, including 15 years as a top-three ranked analyst and six consecutive years in the top spot. Mr. Reicin holds an M.B.A. from Harvard Business School and a B.A. from Brandeis University.

Employees	Founded
	2015

Address: 100 Binney Street, Suite 600 Cambridge, Ma 02142

Telephone: (617) 336-7540

Web page: http://www.sigilon.com

First Trade Date	12/4/2020
Status	Priced
Exchange	NASDAQ
Lockup Period Expiration	.Pro
Quiet Period Expiration	.Pro
Old Price Range	-

Share prices ($)

What do you think will happen with the SGTX share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

The lead left underwriter: Morgan Stanley

Over the last 12 months Since the beginning of the year

IPOs led by the firm	.Pro
Profitability of conducted IPOs  ?	.Pro
1st day change  ?	.Pro
Change for the first 3 months  ?	.Pro

IPOs led by the firm	.Pro
Profitability of conducted IPOs  ?	.Pro
1st day change  ?	.Pro
Change for the first 3 months  ?	.Pro

Underwriters
Morgan Stanley/ Jefferies/ Barclays/ Canaccord Genuity
CO-Managers
-